Capricor Therapeutics (NASDAQ: CAPR) closed Tuesday’s regular session down about 2% at $8.57, extending a rough stretch that had already left the stock down roughly 14% for the month and about 70% year-to-date. Then, after the bell, everything changed in a matter of minutes: shares surged as much as 20% in after-hours trading after new long-term data on its lead Duchenne muscular dystrophy therapy landed at a major medical conference. By the latest quote, CAPR sits at $9.98, down $0.44 (-4.88%) over the past week even after the pop — a reminder of just how beaten-down the stock had become before tonight’s news. Here’s the full technical and fundamental picture behind the Capricor Therapeutics stock forecast heading into the next session.

Capricor Therapeutics Stock Price Today: Full Data Table

Trading & Valuation Snapshot:

Why Capricor Therapeutics Stock Jumped: The HOPE-3 Extension Data, Explained

Capricor’s after-hours pop traces to a single event: new 24-month extension data on deramiocel, the company’s investigational allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy, presented at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan, running September 29 through October 3.

What the new data actually showed:

• Patients who originally received placebo and then switched to deramiocel in the open-label extension phase showed substantially slower deterioration in upper-limb function compared with how they had progressed on placebo, and compared with expected natural-history decline in untreated Duchenne patients.
• Across the full HOPE-3 dataset, deramiocel was shown to slow deterioration in upper-limb function by roughly 54% compared with placebo — the same primary endpoint measure (PUL v2.0) that anchored the pivotal trial.
• B. Riley Securities had already flagged this extension data as a potential near-term stock catalyst in research published ahead of the conference, which helps explain why the stock had already popped 11% the prior week on anticipation alone.
• The timing matters enormously: this data lands roughly seven weeks before the FDA’s November 22, 2026 PDUFA target action date for deramiocel’s Biologics License Application (BLA), giving regulators and investors alike a fresh, positive data point right before the decision window.

The backstory that makes this data so pivotal:

Capricor’s road to this point has been anything but smooth. The FDA issued an initial Complete Response Letter in July 2025, citing insufficient evidence of effectiveness from the original submission. After a contentious back-and-forth over which trial endpoint should anchor the resubmission, the FDA agreed to let Capricor use upper-limb function (PUL v2.0) as the primary endpoint of the HOPE-3 trial, with cardiac function (LVEF) as a key secondary measure. The company resubmitted its BLA in February 2026, the FDA lifted the CRL and resumed review in March, and the full HOPE-3 results were published in The Lancet in July 2026 after independent peer review, hitting statistical significance on the primary endpoint (p=0.029).

That endpoint-switching saga is also central to the multiple securities class action lawsuits now pending against the company — including suits from Kaplan Fox, Robbins LLP, Rosen Law Firm, Pomerantz, and Faruqi & Faruqi — with a lead plaintiff deadline that fell on September 28, 2026, the day before tonight’s rally.

Capricor Therapeutics Stock Chart & Trend: From $40 to Under $9 and Back

CAPR’s 2026 has been one of the more brutal rides in small-cap biotech, and tonight’s bounce, however sharp, still leaves the stock deep in a multi-month downtrend.

The stock remains roughly 75% below its 52-week high of $40.37 even after tonight’s pop, and short interest north of 38% of the float means a meaningful chunk of the recent trading activity has been positioning against the stock — setting up the possibility of a short-covering squeeze if the data momentum extends into Wednesday’s session. For more on how other binary, catalyst-driven biotech setups have traded through similar swings, see our recent Kodiak Sciences stock forecast coverage.

Technical Analysis: Key Support and Resistance Levels for Wednesday

Because tonight’s move happened entirely in after-hours trading, Wednesday’s regular-session open will be the real test of whether the gap holds — and with the stock trading near the bottom of its 52-week range and roughly 28% below its 50-day moving average heading into the news, most nearby technical levels come from Tuesday’s own session and the after-hours print itself.

Levels to Watch:

Technical Signals:

• Tuesday’s regular-session volume of roughly 2.4–3.0 million shares ran well below the stock’s 6.4–6.5 million average, meaning the bulk of the market’s reaction to tonight’s data will show up as fresh volume on Wednesday rather than a continuation of an already-heavy tape.
• A short interest north of 38% of the float is an important wildcard: a stock this heavily shorted can see outsized upside moves if bearish positions get squeezed by a genuinely positive data readout.
• The stock’s low beta of 0.72 is somewhat misleading given the name’s real-world volatility around binary regulatory and data catalysts — beta captures broad-market correlation, not idiosyncratic, news-driven swings like tonight’s.

Prices to Watch Tomorrow: Holding above $8.97 at the open would confirm buyers are defending the bulk of Tuesday night’s gains. A push through $10.28 on strong volume would put the 50-day moving average near $11.90 in play, while a slide back below $8.57 would suggest the market is treating the data as encouraging but not decision-changing ahead of the November PDUFA date.

Analyst Price Targets: A Street Already Split Before Tonight’s News

Capricor’s analyst coverage was already unusually divided heading into this data release — a split that tonight’s positive readout is likely to sharpen rather than resolve.

Consensus Analyst Data:

Recent Rating Activity: B. Riley’s dramatic target increase from $5 to $21 on September 14 came specifically because the firm anticipated this World Muscle Society data release as a stock-moving event — a call that proved directionally accurate even before the full magnitude of tonight’s after-hours move became clear. The gap between B. Riley’s bullish $21 target and Weiss Ratings’ bearish Sell rating underscores how much of Capricor’s valuation still hinges on a binary regulatory outcome just seven weeks away.

Capricor Therapeutics Stock Forecast: Bull Case vs. Bear Case

The Bull Case

• The data keeps getting more supportive, not less. A 54% slowing of upper-limb function deterioration versus placebo, now reinforced by 24-month extension data showing benefit even in patients who switched over from placebo, is a genuinely differentiated efficacy story for a disease with few approved treatment options.
• The regulatory pathway, while bumpy, is still open. The FDA lifted its Complete Response Letter, resumed active review, and has not identified new review issues since — with a firm PDUFA date of November 22, 2026 now in sight.
• Extreme short interest (~38% of float) creates real squeeze potential. A confirmatory data readout or a positive FDA signal ahead of the PDUFA date could trigger outsized upside as short positions unwind.
• The Street’s average target of $27 implies enormous upside from even the post-pop price, and additional pipeline optionality exists through Capricor’s StealthX exosome platform for Duchenne and Pompe disease, even though that program is currently on hold pending regulatory clarity on the core deramiocel program.

The Bear Case

• This is still a binary regulatory bet with a hard deadline. The FDA’s history with this exact application — one Complete Response Letter already issued, a contested endpoint-switching process, and a Form 483 citing one observation from a July 2026 manufacturing inspection — means approval is far from guaranteed.
• Active securities fraud litigation is a real overhang. Multiple law firms have filed class actions alleging the company misled investors, with a lead plaintiff deadline that closed just one day before tonight’s rally — meaning the legal cloud persists regardless of how the data reads.
• The stock is down roughly 70% year-to-date and remains 75% below its 52-week high, a pattern of severe volatility that has repeatedly punished investors who bought into prior rallies on partial data readouts.
• Weiss Ratings’ Sell (D-) rating is a genuine outlier worth weighing, and the divergence between it and B. Riley’s bullish $21 target shows just how unsettled professional opinion remains on this name even after positive news.
• No product revenue exists today, and the entire investment case rests on a single asset clearing a regulatory bar that has already rejected it once.

What Would Change the Story Going Forward

For Capricor’s after-hours pop to hold and extend into a durable re-rating rather than fade by Wednesday’s close, a few concrete developments matter most:

1. Confirmation from additional analyst commentary — watch for updated notes from Piper Sandler, B. Riley, and others digesting the full extension dataset in the coming days.
2. Any signal from the FDA ahead of November 22 — with the PDUFA date now less than two months away, any leak, briefing document release, or advisory committee scheduling news will move the stock sharply in either direction.
3. Developments in the securities litigation — consolidation of the pending class actions or early court rulings could reintroduce downside pressure independent of the clinical story.
4. A technical hold above $8.97 — sustained trading above Tuesday’s regular-session high over the next several sessions would suggest the market is treating tonight’s data as a genuine forward-looking positive rather than a one-night pop.

Absent a fresh negative catalyst, expect CAPR to trade within a wide band between its recent lows near $8 and the analyst-target zone above $20, with the stock’s fate ultimately decided by the FDA’s action on or before November 22.

Bottom Line

Capricor Therapeutics heads into Wednesday with genuinely encouraging long-term efficacy data in hand, delivered at exactly the moment investors needed a reason to believe deramiocel can clear its final regulatory hurdle. But this remains a story defined by binary risk — a contested regulatory history, active securities litigation, and a hard PDUFA deadline just seven weeks away all argue for caution even as the data trend improves. For readers tracking other high-volatility, catalyst-driven biotech and small-cap setups, see our recent Kodiak Sciences stock forecast and ongoing stocks-to-watch coverage.

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, high-volatility biotech stocks like Capricor Therapeutics carry elevated risk, including binary regulatory outcomes and active litigation risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. Support and resistance levels are analytical reference points, not guarantees of future price behavior. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.

About The Author

Nichole Miller

See author's posts